Polycap along with aspirin, reduces as many as 40% heart attacks and strokes

Reduction of risk heart attacks, strokes and other cardiac events, seems to bring about the use of polyhaphy, which, when combined with aspirin, has an efficacy of up to 40%.

This is the conclusion international clinical study in 89 medical centres in nine countries to a total of 5,714 people over 50 years old, with no history of heart disease or stroke and intermediate cardiovascular risk.

The researchers of the five-year TIPS-3 (International Polycap Study) study, led by Professor of Medicine Salim Yusuf of the Canadian McMaster University, published the study in the American medical journal «New England Journal of Medicine». The daily polyhydrate tested contained simvastatin (40 milligrams), atenolol (100 milligrams), hydrochlorothiazide (25 milligrams) and ramipril (10 milligrams), combined with aspirin (75 milligrams).

A comparison was made between those who took polyhap alone or with aspirin and those who used a placebo.

Among those who took the polyhapis, 4.4% experienced a heart attack, stroke or other cardiovascular event, compared to a rate of 5.5% in the control (placebo) group. Among those study participants who took polyhapi along with aspirin, the rate of heart attacks and strokes was 4.1%, compared with 5.8% in the control group (double placebo).

«It's just the beginning of a revolutionary new approach to preventing heart disease. We could save millions of people from serious heart disease or stroke every year with the effective use of polyhaphy and aspirin,» said the cardiologist Dr. Yusuf. «Previous studies of polyhapies, including ours, have shown reduction of risk by 30% to 40%. We hope that our new findings will reinforce the positive trend created by previous research and encourage drug manufacturers to produce such products,» he added.

The researchers pointed out that the polyhapite - which is taken as a molecule once a day, which is a great practical convenience; it is not only effective but also financial, since it incorporates widely used generic medicines. Scientists estimate that if only a third of people who need treatment take polyhapies, millions of serious cardiovascular events could be avoided every year in the future.

The polyhaphy tested is already available in India and a few African countries. Different types of polygraphs are available in Europe and South America, and new polygraphs are already being developed in North America. In North America and China.